Sinogen Biopharma
Pioneering the path for Chinese biotech to reach the U.S. pharmaceutical landscape, fostering the development and licensing of groundbreaking drugs.
Pioneering the path for Chinese biotech to reach the U.S. pharmaceutical landscape, fostering the development and licensing of groundbreaking drugs.
Sinogen Biopharma is pioneering the path for Chinese biotech to reach the U.S. pharmaceutical landscape with a vision to bridge China's biotech innovation to the US pharma market. Founded in 2016, the company is dedicated to fostering the development and licensing of groundbreaking drugs from China. Specializing in Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Sinogen Biopharma received a Series B investment on 31 December 2023 from Hebei Coastal Industry Investment Fund Management, Ningbo Zhuoxuan, and Puxin Capital. This investment signifies a crucial milestone as the company continues its mission to introduce innovative drugs to the global market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | Unknown | 3 |
|
31 Dec 2023 |
| Series B | $10.00M | 3 |
|
23 May 2022 |
| Venture Round | $3.00M | 1 |
|
01 Dec 2021 |
No recent news or press coverage available for Sinogen Biopharma.
We care about your data, and we'd love to use cookies make your experience better.
